British Society for Haematology guidelines for the diagnosis and evaluation of prognosis of Adult Myelodysplastic Syndromes

University Hospitals Dorset NHS Foundation Trust, The Royal Bournemouth Hospital, Bournemouth, The Christie NHS Foundation Trust, Manchester, Kings College Hospital NHS Foundation Trust, London, St. James’s Institute of Oncology, Leeds Teaching Hospitals, Leeds, Aberdeen Royal Infirmary, Aberdeen, UK, Tallaght University Hospital, Trinity College Medical School, Dublin, Ireland, Hull and East Yorkshire Hospitals NHS Trust, Hull, University Hospital of Wales, Cardiff, Newcastle Hospitals NHS Foundation Trust, Newcastle, Worcestershire Acute Hospitals NHS Trust and Birmingham NHS Foundation Trust, Worcester, University College London Cancer Institute, London, University Hospitals Birmingham NHS foundation Trust, Birmingham, Oxford University and Oxford University Hospitals NHS Trust & NHS Blood and Transplant, Oxford, and Great Western Hospitals NHS Foundation Trust, Swindon, UK

[1]  P. Campbell,et al.  SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS , 2020, Blood.

[2]  Benjamin L. Ebert,et al.  Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes , 2019, Nature Medicine.

[3]  M. Cazzola,et al.  Clinical, histopathological and molecular characterization of hypoplastic myelodysplastic syndrome , 2019, Leukemia.

[4]  E. van den Berg,et al.  European recommendations and quality assurance for cytogenomic analysis of haematological neoplasms , 2019, Leukemia.

[5]  P. Campbell,et al.  TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups , 2019, Leukemia.

[6]  A. A. van de Loosdrecht,et al.  Clinical Implication of Multi-Parameter Flow Cytometry in Myelodysplastic Syndromes , 2018, Pathobiology.

[7]  E. Ejerblad,et al.  Prognostic scoring systems for myelodysplastic syndromes (MDS) in a population‐based setting: a report from the Swedish MDS register , 2018, British journal of haematology.

[8]  A. Shimamura,et al.  Genetic predisposition to hematologic malignancies: management and surveillance. , 2017, Blood.

[9]  B. Ebert,et al.  Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions , 2017, Oncotarget.

[10]  E. Vellenga,et al.  Genomic array as compared to karyotyping in myelodysplastic syndromes in a prospective clinical trial , 2017, Genes, chromosomes & cancer.

[11]  M. Cazzola,et al.  Clinical significance of somatic mutation in unexplained blood cytopenia. , 2017, Blood.

[12]  R. Bejar.  CHIP, ICUS, CCUS and other four-letter words , 2017, Leukemia.

[13]  A. Ganser,et al.  Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. , 2017, Blood.

[14]  M. Cazzola,et al.  Time-dependent changes in mortality and transformation risk in MDS. , 2016, Blood.

[15]  E. Roman,et al.  Myeloid malignancies in the real-world: Occurrence, progression and survival in the UK’s population-based Haematological Malignancy Research Network 2004–15 , 2016, Cancer epidemiology.

[16]  Jinming Song,et al.  SNP Array in Hematopoietic Neoplasms: A Review , 2015, Microarrays.

[17]  J. Witte,et al.  MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance. , 2015, Blood.

[18]  S. Barrans,et al.  Targeted sequencing identifies patients with preclinical MDS at high risk of disease progression. , 2015, Blood.

[19]  P. Campbell,et al.  SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts. , 2015, Blood.

[20]  M. Cazzola,et al.  Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM) , 2015, Leukemia.

[21]  E. Zeggini,et al.  Leukemia-Associated Somatic Mutations Drive Distinct Patterns of Age-Related Clonal Hemopoiesis , 2015, Cell reports.

[22]  M. McCarthy,et al.  Age-related clonal hematopoiesis associated with adverse outcomes. , 2014, The New England journal of medicine.

[23]  S. Gabriel,et al.  Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. , 2014, The New England journal of medicine.

[24]  L. Arenillas,et al.  Single nucleotide polymorphism array karyotyping: A diagnostic and prognostic tool in myelodysplastic syndromes with unsuccessful conventional cytogenetic testing , 2013, Genes, chromosomes & cancer.

[25]  M. Stratton,et al.  Clinical and biological implications of driver mutations in myelodysplastic syndromes. , 2013, Blood.

[26]  C Haferlach,et al.  Landscape of genetic lesions in 944 patients with myelodysplastic syndromes , 2013, Leukemia.

[27]  M. Voso,et al.  Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  O. Olopade,et al.  Proposal for the clinical detection and management of patients and their family members with familial myelodysplastic syndrome/acute leukemia predisposition syndromes , 2013, Leukemia & lymphoma.

[29]  D. Steensma.  Dysplasia Has A Differential Diagnosis: Distinguishing Genuine Myelodysplastic Syndromes (MDS) From Mimics, Imitators, Copycats and Impostors , 2012, Current Hematologic Malignancy Reports.

[30]  Luca Malcovati,et al.  Revised international prognostic scoring system for myelodysplastic syndromes. , 2012, Blood.

[31]  D. Neuberg,et al.  Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  C. Pascutto,et al.  Multicenter validation of a reproducible flow cytometric score for the diagnosis of low-grade myelodysplastic syndromes: results of a European LeukemiaNET study , 2012, Haematologica.

[33]  G. Ehninger,et al.  Severe pernicious anemia with distinct cytogenetic and flow cytometric aberrations mimicking myelodysplastic syndrome , 2012, Annals of Hematology.

[34]  V. V. D. van der Velden,et al.  Implementation of flow cytometry in the diagnostic work-up of myelodysplastic syndromes in a multicenter approach: report from the Dutch Working Party on Flow Cytometry in MDS. , 2012, Leukemia research.

[35]  C. Steidl,et al.  New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  A. Órfão,et al.  Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group , 2012, Leukemia.

[37]  M. Stratton,et al.  Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. , 2011, The New England journal of medicine.

[38]  B. Bain,et al.  Idiopathic cytopenia of undetermined significance (ICUS) and idiopathic dysplasia of uncertain significance (IDUS), and their distinction from low risk MDS. , 2011, Leukemia research.

[39]  D. Neuberg,et al.  Clinical effect of point mutations in myelodysplastic syndromes. , 2011, The New England journal of medicine.

[40]  Eva Hellström-Lindberg,et al.  TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  M. McDevitt,et al.  Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies. , 2011, Blood.

[42]  A. Hagemeijer,et al.  Implementation of standardized international karyotype scoring practices is needed to provide uniform and systematic evaluation for patients with myelodysplastic syndrome using IPSS criteria: An International Working Group on MDS Cytogenetics Study. , 2010, Leukemia research.

[43]  Wolfgang Kern,et al.  Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes , 2009, Haematologica.

[44]  J. Bennett,et al.  Diagnostic criteria to distinguish hypocellular acute myeloid leukemia from hypocellular myelodysplastic syndromes and aplastic anemia: recommendations for a standardized approach , 2009, Haematologica.

[45]  C. O'keefe,et al.  Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML. , 2008, Blood.

[46]  N. Shinton.  WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues , 2007 .

[47]  M. Cazzola,et al.  Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  P. Vyas,et al.  Evidence for reduced B-cell progenitors in early (low-risk) myelodysplastic syndrome. , 2005, Blood.

[49]  S Dilly,et al.  Bone marrow pathology , 1949 .

[50]  T Hamblin,et al.  International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.